Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Product development partnerships seek to bridge the healthcare gap
October 11, 2011
By: Faiz kermani
Ph.D.
Not everyone in the world has enjoyed the benefits of the medical advances now available. There exists a tremendous gap between those in established, industrialized countries and those in developing nations. Many people worldwide lack access to the most basic healthcare, with this burden being greatest in countries overwhelmed by poverty. The difference in the impact of diseases between industrialized and developing nations can be huge, and is compounded by poor healthcare infrastructure and a lack of resources. Conditions that predominantly inflict severe health burdens on the world’s poorest people are often described as “neglected diseases,” implying the lack of attention that has been paid to tackling them. The World Health Organization (WHO) has estimated that more than one billion people suffer from one or more neglected diseases.1 Yet, according to figures cited by the TB Alliance, R&D for neglected tropical diseases receives only $1 out of every $100,000 spent worldwide on biomedical research and product development.2 This unfortunate situation has attracted much negative media coverage; major pharmaceutical companies now find themselves publicly criticized for not doing more to develop medicines in this area. Rob Don, director of Drug Discovery and Preclinical Research at the Drugs for Neglected Diseases Initiative (DNDi), outlined how this situation developed: “There was a lack of commercial viability, either as a push (e.g. funding) or pull (e.g. prizes or advance purchasing commitment).” The industry focus on blockbuster development is also a factor. Dr. Reinaldo Menezes Martins, scientific consultant at Bio-Manguinhos/Fiocruz in Brazil, said, “Drugs for neglected diseases are mainly for underdeveloped countries or poor populations, and do not promise the high return on investment being sought by the multinational companies.” Professor Charles Mgone, executive director of the European and Developing Countries Clinical Trials Partnership, has a similar view. “Most of these products are destined for disease-endemic countries whose economies are struggling and constitute very little profit, if any, for the pharmaceutical countries to invest cost-effectively in them,” he explained. “This therefore creates lack of commercial interest and motivation from the private sector to develop these products. Ultimately, the main driver for most pharmaceutical companies to develop these products is to bolster their corporate image.” Derek Ambrosino, a spokesperson for the TB Alliance, gives tuberculosis (TB) as an example. He remarked, “Although TB exists in every country in the world, the majority of cases and mortality occur in the developing world. Since TB is not perceived to be a major health threat in wealthy countries, the market incentives to develop new tools — such as drugs, vaccines, and diagnostics — have been very weak. Therefore efforts to develop urgently needed products to address global health crises like TB were essentially non-existent.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !